CA2758847A1 - Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound - Google Patents

Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Download PDF

Info

Publication number
CA2758847A1
CA2758847A1 CA2758847A CA2758847A CA2758847A1 CA 2758847 A1 CA2758847 A1 CA 2758847A1 CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A1 CA2758847 A1 CA 2758847A1
Authority
CA
Canada
Prior art keywords
capsule
peg
tpgs
pharmaceutical composition
crystallization inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758847A
Other languages
English (en)
French (fr)
Inventor
Sachin Chandran
Rajesh Babulal Gandhi
Jaquan Kalani Levons
Robert Kevin Perrone
Christopher P. Price
Krishnaswamy Srinivas Raghavan
Ismat Ullah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2758847A1 publication Critical patent/CA2758847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2758847A 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Abandoned CA2758847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169,061 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
CA2758847A1 true CA2758847A1 (en) 2010-10-21

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758847A Abandoned CA2758847A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Country Status (14)

Country Link
US (1) US8252821B2 (enExample)
EP (1) EP2419090B1 (enExample)
JP (1) JP2012524092A (enExample)
KR (1) KR20120022766A (enExample)
CN (1) CN102395361A (enExample)
AR (1) AR076305A1 (enExample)
AU (1) AU2010236602A1 (enExample)
BR (1) BRPI1015483A2 (enExample)
CA (1) CA2758847A1 (enExample)
EA (1) EA201101286A1 (enExample)
MX (1) MX2011010514A (enExample)
NZ (1) NZ595335A (enExample)
TW (1) TW201041609A (enExample)
WO (1) WO2010120755A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
EP2485416A4 (en) 2009-10-02 2017-04-05 LG Electronics Inc. Transmission method and device for a downlink reference signal
RU2734128C2 (ru) * 2010-12-16 2020-10-13 Плэтформ Брайтворкс Ту,Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
DK3238709T3 (da) 2011-04-28 2020-09-28 Platform Brightworks Two Ltd Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CA3129356A1 (en) * 2019-02-22 2020-08-27 Janssen Pharmaceutica Nv Pharmaceutical formulations
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
US20230310413A1 (en) * 2020-08-21 2023-10-05 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
PL326700A1 (en) 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
RU2202540C2 (ru) 1996-07-22 2003-04-20 Монсанто Компани Тиолсульфонамидные ингибиторы металлопротеазы
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ512306A (en) 1999-01-27 2003-10-31 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
JP2006522126A (ja) 2003-03-31 2006-09-28 ワイス βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
AU2005237580B2 (en) * 2004-04-28 2011-06-16 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
CA2573372A1 (en) 2004-07-13 2006-01-19 F. Hoffmann-La Roche Ag Sulfonamide derivatives
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
JP2008523146A (ja) * 2004-12-14 2008-07-03 ワイス 神経変性障害の処置および予防のための５−ｈｔ６アゴニストの使用
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
BRPI0707742A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
CN101400349A (zh) * 2006-03-01 2009-04-01 罗斯坎普研究有限责任公司 抑制β-淀粉样蛋白产生的化合物
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN102088855A (zh) 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
MX2011009271A (es) 2009-03-19 2011-09-26 Bristol Myers Squibb Co Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
NZ595335A (en) 2013-03-28
CN102395361A (zh) 2012-03-28
JP2012524092A (ja) 2012-10-11
WO2010120755A1 (en) 2010-10-21
TW201041609A (en) 2010-12-01
KR20120022766A (ko) 2012-03-12
US20100260837A1 (en) 2010-10-14
AU2010236602A1 (en) 2011-10-13
EA201101286A1 (ru) 2012-04-30
EP2419090B1 (en) 2013-02-13
EP2419090A1 (en) 2012-02-22
BRPI1015483A2 (pt) 2016-04-26
AR076305A1 (es) 2011-06-01
MX2011010514A (es) 2011-11-29
US8252821B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
US8252821B2 (en) Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011273519B2 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate
ES2935792T3 (es) Formas farmacéuticas orales de bendamustina y uso terapéutico de las mismas
ES2641637T3 (es) Composiciones farmacéuticas que comprenden ligandos del receptor sigma
PL209704B1 (pl) Kompozycja farmaceutyczna w postaci tabletki do sporządzania zawiesin oraz sposób wytwarzania tabletki do sporządzania zawiesin zawierającej 40-O-(2-hydroksy)etylo-rapamycynę
JPWO2008129846A1 (ja) 医薬組成物
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
JP5749247B2 (ja) 経口用徐放性固形製剤
CN110292575B (zh) 药物组合物
JPWO2010147169A1 (ja) 溶出性の改善された医薬組成物
EP2419086B1 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
CN101896210A (zh) 含有甘露醇和/或微晶纤维素的齐泊腾坦组合物
JP6093762B2 (ja) 徐放性製剤
ES2437916T3 (es) Composición de raloxifeno
EP1572158A1 (en) A new oral immediated release dosage form
US20250352482A1 (en) Amorphous dosage form containing ebselen
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
EP4536191A1 (en) Ebselen containing oral dosage forms

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413